- Home
- ATOS vs VANI Comparison
ATOS vs VANI Comparison
Compare ATOS & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | VANI |
|---|---|---|
| Founded | 2009 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.8M | 92.6M |
| IPO Year | 2012 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ATOS | VANI |
|---|---|---|
| Price | $0.63 | $1.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $6.33 | $4.00 |
| AVG Volume (30 Days) | ★ 1.4M | 225.7K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $0.91 |
| 52 Week High | $1.29 | $1.92 |
Technical Indicators
Market Signals| Indicator | ATOS | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 39.58 |
| Support Level | $0.55 | $1.18 |
| Resistance Level | $0.75 | $1.46 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.90 | 24.20 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About VANI Vivani Medical Inc. (DE)
Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.